<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451071</url>
  </required_header>
  <id_info>
    <org_study_id>000518236</org_study_id>
    <nct_id>NCT03451071</nct_id>
  </id_info>
  <brief_title>Postpartum HPV Vaccination</brief_title>
  <official_title>Postpartum HPV Vaccination: Acceptability, Uptake and Immunogenicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus (HPV)-related cancers are on the rise in the United States. Furthermore,
      greater than 90% of cervical cancer cases are attributable to HPV, and cervical cancer
      disproportionately affects women of color in both incidence and mortality. Due to low HPV
      vaccine uptake in the US, innovative approaches to vaccinating vulnerable populations are
      necessary in order to maximize the cancer prevention potential of this vaccine. The
      puerperium is a time period when women are engaged in the healthcare system and have almost
      universal access to affordable health care. Two prior studies have shown that postpartum HPV
      vaccination is acceptable to patients, and high rates of vaccination were achieved in these
      primarily Hispanic populations. However, data show that the immune response in young women is
      less robust than in adolescents, and no studies have examined immunogenicity in postpartum
      women specifically. We propose an HPV vaccination pilot study in women who receive postpartum
      care at University of Alabama at Birmingham (UAB) hospital. We will examine the
      acceptability, uptake and immunogenicity of the vaccine in the postpartum setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient indication of willingness to accept the vaccine based on survey</measure>
    <time_frame>1 day (at the time of initial recruitment /survey)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uptake of the vaccine doses</measure>
    <time_frame>at 0, 2-3 and 6 months</time_frame>
    <description>Uptake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum titers of vaccine-specific HPV types</measure>
    <time_frame>baseline and 7 months</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HPV-Related Malignancy</condition>
  <arm_group>
    <arm_group_label>Gardasil9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gardasil9</intervention_name>
    <description>Gardasil 9</description>
    <arm_group_label>Gardasil9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postpartum day 0-4 after vaginal or Cesarean delivery at UAB hospital

        Exclusion criteria

          -  Fetal demise or miscarriage, autoimmune disorder, HIV, Hepatitis B/C, chronic steroid
             use, preeclampsia, non-English speaking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haller Smith, MD</last_name>
    <phone>2059344986</phone>
    <email>hjsmith@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Dilley, MD</last_name>
    <email>sdilley@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haller Smith, MD</last_name>
      <phone>205-934-4986</phone>
      <email>hjsmith@uab.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Warner Huh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

